Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing - Wikidata - wikimedia - TriplyDB

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing

http://www.wikidata.org/entity/Q27008360

about

Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process.Applications of CYP450 testing in the clinical setting From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource Combinatorial Versus Individual Gene Pharmacogenomic Testing in Mental Health: A Perspective on Context and Implications on Clinical Utility Impact of New Genomic Technologies on Understanding Adverse Drug Reactions Economic evaluations of personalized medicine: existing challenges and current developments Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?Pharmacogenomics and cardiovascular disease Pharmacogenomics discovery and implementation in genome-wide association studies era Stroke genetics: prospects for personalized medicine Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation Pharmacogenomics of hypertension and heart disease Use of contemporary genetics in cardiovascular diagnosis Respiratory review of 2014: pulmonary thromboembolism Advantages of Array-Based Technologies for Pre-Emptive Pharmacogenomics Testing The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity Pharmacogenomics: personalizing pediatric heart transplantation Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis Pharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions: Top 10 Opportunities and Challenges for the Next Decade Analysis of Genetic Variation in CYP450 Genes for Clinical Implementation Warfarin Pharmacogenetics: New Life for an Old Drug A New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish Population Incidence of Exposure of Patients in the United States to Multiple Drugs for Which Pharmacogenomic Guidelines Are Available The Active Metabolite of Warfarin (3'-Hydroxywarfarin) and Correlation with INR, Warfarin and Drug Weekly Dosage in Patients under Oral Anticoagulant Therapy: A Pharmacogenetics Study Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics Integrating dynamic mixed-effect modelling and penalized regression to explore genetic association with pharmacokinetics Progress towards the integration of pharmacogenomics in practice Electronic Medical Record-Integrated Pharmacogenomics and Related Clinical Decision Support Concepts.Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association Open access integrated therapeutic and diagnostic platforms for personalized cardiovascular medicine Use of genetic data to guide therapy in arterial disease.Merging Electronic Health Record Data and Genomics for Cardiovascular Research: A Science Advisory From the American Heart Association.Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model.Towards the clinical implementation of pharmacogenetics in bipolar disorder.The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population.Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study.The allele frequency of CYP2C9 and VKORC1 in the Southern Khorasan population.Implementation of pharmacogenetics: the University of Maryland Personalized Anti-platelet Pharmacogenetics Program.Pharmacogenetics of warfarin: challenges and opportunities.

P2860

Q24567778-A00DB1B6-8E15-4C0B-BC5D-DA40BC2D7726 Q24621760-4D706BA4-7757-422B-B157-E587FA4490B9 Q24632079-C30F5B55-8805-4274-B2CF-B1F442700274 Q26775813-9BEAFBA9-5363-47C5-B2F6-87F3910AFA0A Q26787099-153EC32F-8C58-4775-B049-A1F3BC9D797D Q26797183-787DC517-FFEA-4773-858E-A4F6C6E229AF Q26822796-C67AF3F2-42F7-4605-A469-944EC9DB3E63 Q26823542-90BA1E1E-5BC6-4821-A6BF-0E1D248ED34A Q26997380-EE40F4DC-D046-4AAC-8F0D-2235190AAAE9 Q27001573-A2DC4787-FAFD-4DD0-AEB6-93DCFB924A9D Q27006885-97AFAB71-C18A-4972-9CB4-D096C7564C7C Q27011524-4B3FB6C1-3641-41C1-AD69-7328AB6F7EC8 Q27015722-0EB46521-B55F-4A58-8C33-7BFDEF0533DF Q27025306-7C64170C-4F39-4A33-996A-A30B7C6B496C Q27028131-B9099C03-B9D1-40FD-8764-F073DC413ED5 Q28079766-41907DFA-C1A5-46E6-B047-C30BA3B3B4F8 Q28080256-2207C427-73E8-4614-A8FF-CF6A4222755D Q28081200-7224955B-FBE2-4CD9-A944-F1DA1DF902C8 Q28276605-36C24CB8-C962-4A18-8CD2-8384A49B6F2E Q28392069-1480E943-1CCD-4C32-AE79-E4648DF48CDE Q28468449-F858A73B-CC09-486F-A7ED-EF08E56BAB83 Q28468726-CB1D9E06-E0CD-47DD-8736-713C00AF7EE1 Q28550740-6BC7362E-9D37-4843-9C1E-E3A3FDA48977 Q28552832-15B77653-88D0-477C-B6C2-F56CB1F46FED Q28553937-36FE6875-00BE-4CDC-ABC9-F32B876C53FF Q28601852-BCFD78E8-148D-47BE-A79F-F7454E49E863 Q28650281-B66F707F-5042-42C0-B9E6-2042C10FF7C0 Q28652270-BEAAA3F5-633B-4F6A-8223-6D3747052E44 Q30234897-A6E04918-179E-4812-BCF9-187B45A56AC5 Q30359686-625C12CD-E228-4736-8FC5-2FE6EFAB1406 Q30487537-5AFEAD4B-D105-4154-A6B5-C777D348D96C Q30978916-532098E9-E505-46B8-BEC8-D9A01778B578 Q31058146-0B3FA602-0B01-423F-8728-EAF19E280F3C Q31131437-463BBD91-4550-4A40-9D18-2D39FAB93962 Q33688133-68D55F85-8E08-471D-BDC8-D236F7023AAE Q33707218-35A996B1-E884-478B-80C2-35102ED7A332 Q33770184-1ED90471-CF7B-4989-A661-44A5929CAB88 Q33782314-42601196-73F4-43C9-88C2-DD171ED74147 Q33792154-1ADDFF2B-6127-414E-B406-94364100AF4D Q33819050-B9C78B3E-DF6E-4D82-83FA-DD02B71DE507

P2860

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing

http://www.wikidata.org/entity/Q27008360

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

Clinical Pharmacogenetics Impl ...... genotypes and warfarin dosing

@ast

Clinical Pharmacogenetics Impl ...... genotypes and warfarin dosing

@en

Clinical Pharmacogenetics Impl ...... genotypes and warfarin dosing

@nl

type

label

Clinical Pharmacogenetics Impl ...... genotypes and warfarin dosing

@ast

Clinical Pharmacogenetics Impl ...... genotypes and warfarin dosing

@en

Clinical Pharmacogenetics Impl ...... genotypes and warfarin dosing

@nl

prefLabel

Clinical Pharmacogenetics Impl ...... genotypes and warfarin dosing

@ast

Clinical Pharmacogenetics Impl ...... genotypes and warfarin dosing

@en

Clinical Pharmacogenetics Impl ...... genotypes and warfarin dosing

@nl

P1433

Q27008360-F5DF9FF9-DBE9-4C54-B3CB-DFF3B5988D21

P1476

Q27008360-C8943324-5E91-49DA-83EC-9A28F2630B67

P2093

Q27008360-0BDCE63D-F2CD-4B5E-A1AA-F193C96CF965

Q27008360-211481A5-8D32-4577-9677-7CA851236C25

Q27008360-48E76C16-6314-4EA5-ADA0-37B94724978F

Q27008360-4C305672-6F1D-4E48-BF1B-DC888FD5663F

Q27008360-4E29CE92-E5E0-49C5-A722-423DD59E1651

Q27008360-52DD4644-0D3C-45D8-8CF7-CCECD6045546

Q27008360-594D6233-65DC-4901-B696-C982B44E95B6

Q27008360-73B530DB-856D-488D-B3F9-223F24750762

Q27008360-A9ADE6CB-E147-4C2B-9D29-79FD61F2507B

Q27008360-A9E1FE46-D905-4E68-94BE-1A9E5C81E2AC

P2860

Q27008360-08353BD7-B294-4458-8A51-EF16ED1F1D41

Q27008360-09426EDE-9E99-49B6-84E2-F29EB6511F21

Q27008360-0A0F73B6-419B-4A38-AE33-A930380EB926

Q27008360-0C0E1613-4488-483C-AB4D-1B8EECA1DFDB

Q27008360-1E0E107E-0933-4D36-9445-0440C3494168

Q27008360-2131689B-BB58-4EEB-BC2F-089751891294

Q27008360-2EE3397A-02B9-4E1E-8955-B62C1E452E9A

Q27008360-3726C168-AAFD-456A-B283-D07CF2C68CC8

Q27008360-3C352FAB-2A15-4EC8-9598-E6D6FC9B71D3

Q27008360-592F066A-EA25-4992-906E-429587FCE98B

P304

Q27008360-BCA90FCB-409B-4009-99D5-566D5FB3831F

P31

Q27008360-CB7EE3D6-6B54-43CC-B2DC-EDF80F242B29

P3181

Q27008360-B251B02A-D2C5-4081-A473-295E6724B6BE

P356

Q27008360-4901F5F6-333D-4B2A-A034-AA19325B3EC8

P407

Q27008360-08077CC2-1C88-4AF1-BAFB-8034D4FF6620

P433

Q27008360-C77FD425-4432-46F1-AF83-9B54DA5A10F9

P478

Q27008360-21A64E2D-BBEE-4873-B1C4-785FDC6276CA

P50

Q27008360-7CE2F43E-5D11-4211-93FF-5EC73987F25A

Q27008360-7CFBDFC6-08F9-4A29-A50A-6EBDBF77664D

Q27008360-84072CD7-C7F4-46EC-B03F-B3BE67C27C30

P577

Q27008360-6E078F60-4109-4C7F-AC6E-66947D61ADEB

P5875

Q27008360-4588FE88-D46E-486F-B3C3-9F78B6A7A70A

P698

Q27008360-2D728DDE-9C0A-4F1F-9E57-56BE21CDA9C5

P932

Q27008360-6EAF49C7-B5F2-4CF0-BD49-DEE24ACEF344

P3181

P356

P1433

Clinical Pharmacology & Therapeutics

P1476

Clinical Pharmacogenetics Impl ...... genotypes and warfarin dosing

@en

P2093

B F Gage

http://www.w3.org/2001/XMLSchema#string

C M Stein

http://www.w3.org/2001/XMLSchema#string

J A Johnson

http://www.w3.org/2001/XMLSchema#string

J L Anderson

http://www.w3.org/2001/XMLSchema#string

L Gong

http://www.w3.org/2001/XMLSchema#string

M T M Lee

http://www.w3.org/2001/XMLSchema#string

R B Altman

http://www.w3.org/2001/XMLSchema#string

S A Scott

http://www.w3.org/2001/XMLSchema#string

S E Kimmel

http://www.w3.org/2001/XMLSchema#string

T E Klein

http://www.w3.org/2001/XMLSchema#string

P2860

CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

Identification of the gene for vitamin K epoxide reductase

Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

Estimation of the warfarin dose with clinical and pharmacogenetic data.

Integration of genetic, clinical, and INR data to refine warfarin dosing.

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin.

Oral anticoagulation and risk of death: a medical record linkage study.

P304

625-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

535403

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/CLPT.2011.185

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

90

http://www.w3.org/2001/XMLSchema#string

P50

Munir Pirmohamed

Michelle Whirl-Carrillo

P577

2011-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51626807

http://www.w3.org/2001/XMLSchema#string

P698

21900891

http://www.w3.org/2001/XMLSchema#string

P932

3187550

http://www.w3.org/2001/XMLSchema#string